Tg Therapeutics (TGTX) Return on Capital Employed (2012 - 2026)

Tg Therapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 13.48% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 39.0% year-over-year to 13.48%; the TTM figure through Mar 2026 stood at 13.48% (up 39.0% YoY), while the FY2025 annual figure was 18.5%, up 695.0% from the prior year.
• Return on Capital Employed was 13.48% for Q1 2026 at Tg Therapeutics, down from 13.85% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 30.13% in Q2 2024 to a low of 143.13% in Q4 2022.
• Historically, Return on Capital Employed has averaged 40.07% across 5 years, with a median of 0.99% in 2023.
• The sharpest annual moves came in 2022 and 2024: Return on Capital Employed sank 4929 bps in 2022, then jumped 17245 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 143.13% in 2022, then surged by 101 bps to 0.99% in 2023, then surged by 761 bps to 8.54% in 2024, then jumped by 62 bps to 13.85% in 2025, then decreased by 3 bps to 13.48% in 2026.
• The last three Return on Capital Employed figures came in at 13.48% (Q1 2026), 13.85% (Q4 2025), and 14.54% (Q3 2025), per Business Quant data.